VIRAMUNE XR Drug Patent Profile

When do Viramune Xr patents expire, and when can generic versions of Viramune Xr launch?

Viramune Xr is a drug marketed by Boehringer Ingelheim and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

The generic ingredient in VIRAMUNE XR is nevirapine. There is one drug master file entry for this compound. Six suppliers are listed for this compound. Additional details are available on the nevirapine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Viramune Xr

A generic version of VIRAMUNE XR was approved as nevirapine by AUROBINDO on May 22^nd, 2012.

Summary for VIRAMUNE XR

US Patents:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	142
Clinical Trials:	42
Drug Prices:	Drug price information for VIRAMUNE XR
DailyMed Link:	VIRAMUNE XR at DailyMed

See drug prices for VIRAMUNE XR

Recent Clinical Trials for VIRAMUNE XR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Witwatersrand, South Africa	Phase 4
National Institutes of Health (NIH)	Phase 4
Columbia University	Phase 4

See all VIRAMUNE XR clinical trials

Paragraph IV (Patent) Challenges for VIRAMUNE XR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VIRAMUNE XR	Extended-release Tablets	nevirapine	400 mg	201152	3	2013-06-21

US Patents and Regulatory Information for VIRAMUNE XR

VIRAMUNE XR is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	VIRAMUNE XR	nevirapine	TABLET, EXTENDED RELEASE;ORAL	201152-002	Nov 8, 2012		DISCN	Yes	No
Boehringer Ingelheim	VIRAMUNE XR	nevirapine	TABLET, EXTENDED RELEASE;ORAL	201152-001	Mar 25, 2011		DISCN	Yes	No

EU/EMA Drug Approvals for VIRAMUNE XR

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Boehringer Ingelheim International GmbH	Viramune	nevirapine	EMEA/H/C/000183Tablets and oral suspensionViramune is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1-infected adults, adolescents, and children of any age.Most of the experience with Viramune is in combination with nucleoside reverse-transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after Viramune should be based on clinical experience and resistance testing.50- and 100-mg prolonged-release tabletsViramune is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1-infected adolescents and children three years and above and able to swallow tablets.Prolonged-release tablets are not suitable for the 14-day lead-in phase for patients starting nevirapine. Other nevirapine formulations, such as immediate-release tablets or oral suspension should be used.Most of the experience with Viramune is in combination with nucleoside reverse-transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after Viramune should be based on clinical experience and resistance testing.400-mg prolonged-release tabletsViramune is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1-infected adults, adolescents and children three years and above and able to swallow tablets.Prolonged-release tablets are not suitable for the 14-day lead-in phase for patients starting nevirapine. Other nevirapine formulations, such as immediate-release tablets or oral suspension should be used.Most of the experience with Viramune is in combination with nucleoside reverse-transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after Viramune should be based on clinical experience and resistance testing.	Authorised	no	no	no	1998-02-04
Teva B.V.	Nevirapine Teva	nevirapine	EMEA/H/C/001119Nevirapine Teva is indicated in combination with other anti-retroviral medicinal products for the treatment of HIV 1 infected adults, adolescents, and children of any age.Most of the experience with nevirapine is in combination with nucleoside reverse transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after nevirapine should be based on clinical experience and resistance testing.	Withdrawn	yes	no	no	2009-11-30

International Patents for VIRAMUNE XR

See the table below for patents covering VIRAMUNE XR around the world.

Country	Patent Number	Title	Estimated Expiration
African Regional IP Organization (ARIPO)	179	5 11-Dihydro-6H-Dipyrido (3, 2-b:2', 3'-e) (1,4) Diazepines and their use in the prevention and treatment of HIV infection.
African Regional IP Organization (ARIPO)	189	5,11 Dihydro-6H-dipyrido (3,2-b:2, 3 -e)(1,4)-diazepin-6-ones and thions and their use for the treatment of aids.
African Regional IP Organization (ARIPO)	9000188

Supplementary Protection Certificates for VIRAMUNE XR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0429987	990022	Netherlands		990022, 20101116, EXPIRES: 20121222
0429987	SPC/GB99/020	United Kingdom		PRODUCT NAME: NEVIRAPINE = 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO(3,2-B:2',3'-E)(1,4)DIAZEPIN-6-ONE OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF; REGISTERED: CH 54393 19971223; UK EU/1/97/055/001 19980205
0429987	C990022	Netherlands		PRODUCT NAME: NEVIRAPINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NATL REGISTRATION NO/DATE: EU/1/97/055/001 19980205; FIRST REGISTRATION: CH 54393 19971223

Viramune XR Market Dynamics and Financial Trajectory

Last updated: August 27, 2026

Viramune XR is the extended-release formulation of nevirapine, a non-nucleoside reverse transcriptase inhibitor used with other antiretroviral medicines to treat HIV-1 infection. The product received U.S. FDA approval in 2011 under NDA 203236 and was marketed by Boehringer Ingelheim. Its commercial trajectory has been shaped by three factors: rapid displacement by integrase inhibitor regimens, broad generic availability of immediate-release nevirapine, and limited differentiation from lower-cost alternatives.

Boehringer Ingelheim does not publicly report standalone Viramune XR revenue. Public financial disclosures group HIV products or omit individual products, preventing a reliable product-level revenue series. The available evidence supports a mature-to-declining commercial profile rather than a growth asset.

What is Viramune XR and how does it compare with Viramune immediate release?

Viramune XR contains nevirapine in an extended-release tablet designed for once-daily administration. Viramune immediate release requires twice-daily dosing after an initial lead-in period. Both products inhibit HIV-1 reverse transcriptase, but neither has the clinical or commercial position of newer integrase strand transfer inhibitor-based regimens.

Attribute	Viramune XR	Viramune immediate release
Active ingredient	Nevirapine	Nevirapine
Drug class	NNRTI	NNRTI
Administration	Once daily	Twice daily after lead-in
U.S. approval	2011	Earlier approval
Sponsor	Boehringer Ingelheim	Boehringer Ingelheim
Primary differentiation	Dosing convenience	Established low-cost therapy
Competitive position	Niche and mature	Generic, low-price market
Main substitutes	Integrase inhibitor combinations	Integrase inhibitor combinations and generic NNRTIs

The extended-release product improved dosing convenience but did not materially change nevirapine's position in treatment guidelines. Current HIV treatment practice generally favors regimens based on dolutegravir or bictegravir because of efficacy, resistance profiles, tolerability, and treatment simplicity [1].

What is the FDA regulatory status of Viramune XR?

Viramune XR was approved by the FDA for combination treatment of HIV-1 infection in adults and children at least six years old who can swallow tablets. The product is administered after an initial period of immediate-release nevirapine treatment to reduce the risk of serious rash and hepatic toxicity [2].

The approval did not create a new therapeutic class. It extended the commercial life of nevirapine through a modified-release formulation and once-daily dosing.

FDA approval timeline

Date	Regulatory event
1996	Viramune immediate-release tablets approved in the United States
2011	Viramune XR approved under NDA 203236
2012 onward	Extended-release product marketed for once-daily dosing
Subsequent years	Treatment guidelines increasingly shifted toward integrase inhibitor-based regimens

Viramune XR's regulatory value was therefore incremental. The product addressed adherence convenience but entered a therapeutic market already moving toward newer mechanisms.

What patents protect Viramune XR?

Viramune XR was protected primarily through formulation and modified-release intellectual property rather than a new-molecule patent. Nevirapine itself was an older active ingredient when the extended-release product launched.

The commercial importance of the patent estate was limited by several factors:

1. The underlying nevirapine molecule was no longer commercially exclusive.
2. Immediate-release generic nevirapine was available.
3. Competitors could target the same therapeutic use with different formulations.
4. Clinical guidelines did not require the extended-release version.

The FDA Orange Book is the controlling source for patents listed against an approved U.S. product. Product-specific patent listings and exclusivity status can change as FDA records are updated. The extended-release formulation's protection did not provide the same barrier to competition as a new chemical entity patent [3].

What formulations are protected by Viramune XR patents?

The relevant intellectual-property strategy centered on controlled-release nevirapine tablets. Such patents generally protect aspects of tablet composition, release characteristics, dosing, or manufacturing rather than the active ingredient itself.

Formulation patents can be commercially useful when:

• the dosage form produces a clinically meaningful benefit;
• the formulation is difficult to design around;
• prescribers value the delivery advantage;
• reimbursement supports a premium price.

Viramune XR had limited pricing power because once-daily dosing was competing against newer once-daily combination regimens, not only twice-daily nevirapine.

When did Viramune XR lose exclusivity?

Viramune XR did not retain meaningful market exclusivity after the broader nevirapine franchise matured. The precise end date for any listed formulation patent should be determined from the applicable Orange Book records and patent-family data. Public financial information does not identify a distinct exclusivity-driven revenue period for Viramune XR.

The product's effective commercial exclusivity was weaker than its formal patent position. Generic immediate-release nevirapine created therapeutic and pricing pressure before a direct extended-release substitute was required. Physicians and payers could switch patients to other antiretroviral combinations without waiting for a generic equivalent of the same dosage form.

How many patents cover Viramune XR?

The number of commercially material patents is more important than the raw number of family members. Viramune XR's protection was likely concentrated in a limited formulation estate associated with extended-release nevirapine. Patent-family continuations, foreign counterparts, and expired members can inflate the apparent count without creating additional market barriers.

The relevant competitive questions are:

• whether a patent was listed in the Orange Book;
• whether the patent remained enforceable;
• whether a generic applicant could design around the release mechanism;
• whether the market was large enough to justify a patent challenge.

For Viramune XR, the low commercial value of the product reduced the incentive for extensive patent litigation.

Which companies challenged Viramune XR, and what Paragraph IV risks existed?

There is no broad, high-profile Paragraph IV litigation record comparable with major oncology, immunology, or diabetes products. The principal risk came from substitution into generic nevirapine or alternative branded antiretroviral regimens.

A generic applicant seeking approval for an extended-release version could challenge listed patents through an Abbreviated New Drug Application and Paragraph IV certification. The commercial case would depend on expected volume, development cost, formulation complexity, and the ability to capture patients from the branded product.

The more significant market threat was indirect:

• generic immediate-release nevirapine reduced the value of branded nevirapine;
• newer antiretroviral products displaced the class;
• fixed-dose combinations simplified treatment;
• managed-care formularies favored lower-cost or guideline-preferred regimens.

What is the litigation and settlement status of Viramune XR?

Viramune XR has not generated a publicly prominent U.S. patent-litigation profile. There is no widely reported settlement agreement that materially delayed generic entry or preserved a major exclusivity position.

The absence of major litigation is commercially consistent with the product's market size and declining strategic relevance. Generic companies typically prioritize products with larger addressable markets, stronger pricing, or clearer formulation opportunities.

What is the competitive landscape for Viramune XR?

Viramune XR competes in two separate markets: the legacy NNRTI market and the broader HIV treatment market.

Competitive segment	Representative products	Effect on Viramune XR
Generic NNRTIs	Generic nevirapine, efavirenz	Limits price and retention
Modern single-tablet regimens	Biktarvy, Triumeq, Dovato and related products	Replaces older regimens
Integrase inhibitor combinations	Tivicay-based and other INSTI regimens	Preferred in many treatment settings
Long-acting therapy	Cabenuva	Creates an alternative to daily oral therapy
Fixed-dose generic combinations	Various low-cost combinations	Increases payer pressure

Biktarvy, marketed by Gilead Sciences, and dolutegravir-based regimens from ViiV Healthcare have had a substantially stronger contemporary commercial position. These products offer better alignment with current treatment guidelines and physician prescribing patterns.

How has Viramune XR revenue changed over time?

Boehringer Ingelheim does not disclose Viramune XR revenue as a standalone line item. A precise annual sales curve cannot be derived from the company's public reports.

The financial trajectory can be divided into four phases:

Launch and formulation expansion

Viramune XR entered the market as a lifecycle-management product. The value proposition was once-daily dosing rather than a new mechanism or improved antiviral potency.

Early commercialization

Initial uptake came from patients already receiving nevirapine and from prescribers seeking simpler dosing. Conversion was constrained because treatment guidelines and formularies increasingly favored other classes.

Erosion from therapeutic substitution

The largest revenue pressure came from newer regimens rather than direct generic substitution. A patient could move from nevirapine to an integrase inhibitor product, eliminating the relevance of the XR formulation entirely.

Mature or declining phase

The product's likely revenue profile is characterized by declining volume, limited pricing power, and low promotional priority. No public evidence indicates that Viramune XR became a material growth contributor for Boehringer Ingelheim after the early post-launch period.

What generic launch risks exist for Viramune XR?

The generic launch risk is moderate for the formulation but high for the underlying therapeutic franchise.

A direct generic extended-release product would face technical requirements related to:

• release-rate matching;
• tablet formulation;
• bioequivalence;
• dose proportionality;
• manufacturing consistency;
• potential food-effect considerations.

Those barriers are meaningful but not equivalent to the barriers for a complex biologic or long-acting injectable. The larger issue is market economics. A generic manufacturer may have limited incentive to develop the product if most HIV prescribing has shifted to newer regimens.

Does Viramune XR face biosimilar risk?

No. Viramune XR is a small-molecule oral drug, not a biologic. It is subject to the generic-drug pathway rather than the FDA biosimilar pathway.

The relevant regulatory risks are ANDA filings, patent certifications, bioequivalence requirements, and state or payer substitution. Biosimilar competition does not apply.

How strong is the Viramune XR patent estate?

The estate is commercially weak to moderate. It may have provided useful protection for the extended-release dosage form, but it did not protect the active ingredient or the broader HIV treatment indication.

Patent strength is reduced by:

• the age of nevirapine;
• availability of generic immediate-release versions;
• therapeutic substitution into integrase inhibitors;
• limited premium value for once-daily dosing;
• declining market demand;
• lack of evidence of major patent disputes.

The formulation estate may still matter for a narrow direct-generic challenge, but it is unlikely to support significant long-term exclusivity value.

What is the geographic market outlook for Viramune XR?

The United States is the most important jurisdiction for patent and regulatory analysis because FDA approval and Orange Book listings determine U.S. generic-entry mechanics. European and other markets have separate patent, regulatory, and reimbursement frameworks.

In lower-income and middle-income countries, nevirapine has historically been used because of cost and availability. That demand is concentrated in public-health and generic channels, where a branded extended-release tablet has limited pricing power. International sales therefore do not compensate for declining branded demand in developed markets.

Key Takeaways

• Viramune XR is once-daily extended-release nevirapine, approved by the FDA in 2011.
• Its commercial differentiation was dosing convenience, not a new mechanism.
• Boehringer Ingelheim does not publicly disclose standalone Viramune XR revenue.
• The product's financial trajectory is best characterized as mature and declining.
• Integrase inhibitor-based regimens created greater pressure than direct generic substitution.
• Formulation patents may have protected the extended-release dosage form, but the nevirapine molecule was already commercially mature.
• Viramune XR is exposed to generic-drug risk, not biosimilar risk.
• No major publicly reported Paragraph IV litigation or settlement appears to have preserved a significant market position.
• The product has limited current strategic value compared with modern single-tablet and long-acting HIV therapies.

FAQs About Viramune XR Market and Patent Risk

Is Viramune XR still a commercially important HIV drug?

No. Its commercial importance is limited by generic nevirapine availability and the widespread use of integrase inhibitor-based therapies.

Who originally marketed Viramune XR?

Boehringer Ingelheim developed and marketed Viramune XR in the United States.

Can a generic company substitute immediate-release nevirapine for Viramune XR?

Automatic substitution depends on product-specific FDA equivalence ratings, state law, and prescriber instructions. A therapeutic switch is clinically and legally distinct from automatic generic substitution.

Is Viramune XR included in the FDA Orange Book?

FDA-approved prescription products are evaluated through FDA databases, including the Orange Book framework for therapeutic equivalence and listed patents. The current status of any specific patent listing must be read from the applicable FDA record [3].

What drug class replaced Viramune XR in HIV treatment?

Integrase strand transfer inhibitor-based regimens have largely displaced older nevirapine-based treatment in contemporary HIV care because of efficacy, tolerability, resistance, and regimen simplicity [1].

References

1. U.S. Department of Health and Human Services. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Clinicalinfo.HIV.gov.

2. U.S. Food and Drug Administration. (2011). Viramune XR prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.